Rothschild Investment LLC’s Arcutis Biotherapeutics ARQT Stock Holding History

Rothschild Investment LLC’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14K	Sell	534 -31	-5%	-$722	﹤0.01%	1704
2026 Q1	$13.3K	Buy	565 +36	+7%	+$919	﹤0.01%	1579
2025 Q4	$15.4K	Buy	529 +34	+7%	+$870	﹤0.01%	1416
2025 Q3	$9.33K	Buy	495 +255	+106%	+$4.02K	﹤0.01%	1469
2025 Q2	$3.37K	Sell	240 -40	-14%	-$561	﹤0.01%	1712
2025 Q1	$4.38K	Buy	280 +140	+100%	+$1.97K	﹤0.01%	1502
2024 Q4	$1.95K	Buy	140 +5	+4%	+$55	﹤0.01%	1817
2024 Q3	$1.26K	Buy	135 +75	+125%	+$740	﹤0.01%	1997
2024 Q2	$558	Buy	60 +45	+300%	+$407	﹤0.01%	1943
2024 Q1	$149	Buy	+15	New	+$112	﹤0.01%	1911

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Rothschild Investment LLC's ARQT Position: Q2 2026 in Review

Rothschild Investment LLC reduced its Arcutis Biotherapeutics (ARQT) stake by 5.5% in Q2 2026, selling an estimated $722 and leaving 534 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #1704.

Rothschild Investment LLC first reported a position in ARQT in Q1 2024 and has held it in 10 quarters since. The position peaked at $15.4K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Rothschild Investment LLC held 534 shares of Arcutis Biotherapeutics worth $14K as of Q2 2026.
Rothschild Investment LLC sold 31 Arcutis Biotherapeutics shares in Q2 2026, an estimated $722.
Arcutis Biotherapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #1704 holding.
Rothschild Investment LLC first reported a position in Arcutis Biotherapeutics in Q1 2024 and has held it in 10 quarters since.
Rothschild Investment LLC's Arcutis Biotherapeutics position peaked at $15.4K in Q4 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.